Gelissen, Liza M.Y., Loveless, Sam ORCID: https://orcid.org/0000-0002-5124-4115, Toorop, Alyssa A., Howlett, Jayne, Loeff, Floris C., Rispens, Theo, Killestein, Joep, Tallantyre, Emma C. ORCID: https://orcid.org/0000-0002-3760-6634 and van Kempen, Zoé L.E.
2024.
Subcutaneous administration of natalizumab can lead to lower drug concentrations compared to intravenous administration.
Multiple Sclerosis and Related Disorders
90
, 105796.
10.1016/j.msard.2024.105796
Item availability restricted. |
PDF
- Accepted Post-Print Version
Restricted to Repository staff only until 29 July 2025 due to copyright restrictions. Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (255kB) |
Abstract
Background Several studies reported lower drug concentrations with subcutaneous natalizumab compared to intravenous natalizumab. With the emergence of extended interval dosing, gaining more insight into lower concentrations after subcutaneous administration is essential. Methods We compared serum trough concentrations between subcutaneous and intravenous administration within a matched cohort (n = 50). Results Subcutaneous administration (n = 25) was associated with lower concentrations compared to intravenous administration (n = 25) (log-B=-0.28, p = 0.01). In an exploratory group of 11 patients receiving extended interval dosing of subcutaneous natalizumab, the median trough concentration was even lower. Conclusion Subcutaneous natalizumab can lead to lower drug concentrations, potentially limiting extended interval dosing.
Item Type: | Article |
---|---|
Date Type: | Publication |
Status: | Published |
Schools: | Medicine MRC Centre for Neuropsychiatric Genetics and Genomics (CNGG) |
Publisher: | Elsevier |
ISSN: | 2211-0348 |
Date of First Compliant Deposit: | 8 October 2024 |
Date of Acceptance: | 29 July 2024 |
Last Modified: | 07 Nov 2024 19:15 |
URI: | https://orca.cardiff.ac.uk/id/eprint/172662 |
Actions (repository staff only)
Edit Item |